217 related articles for article (PubMed ID: 11241242)
21. Relationship among initial serum prostate specific antigen, prostate specific antigen progression and prostate cancer detection at repeat screening visits.
Candas B; Labrie F; Gomez JL; Cusan L; Chevrette E; Lévesque J; Brousseau G
J Urol; 2006 Feb; 175(2):510-6; discussion 516-7. PubMed ID: 16406983
[TBL] [Abstract][Full Text] [Related]
22. Detection rate of prostate cancer on biopsy according to serum prostate-specific antigen in Korean men: a multicenter study.
Yang WJ; Lee DH; Chung BH; Cho JS; Choi YD; Kim SJ; Cho IR; Kim HS; Kim CI; Hong SJ;
Urology; 2006 Feb; 67(2):333-6. PubMed ID: 16461083
[TBL] [Abstract][Full Text] [Related]
23. Results of a randomized, population-based study of biennial screening using serum prostate-specific antigen measurement to detect prostate carcinoma.
Hugosson J; Aus G; Lilja H; Lodding P; Pihl CG
Cancer; 2004 Apr; 100(7):1397-405. PubMed ID: 15042673
[TBL] [Abstract][Full Text] [Related]
24. Detection of prostatic carcinoma: the role of TRUS, TRUS guided biopsy, digital rectal examination, PSA and PSA density.
Men S; Cakar B; Conkbayir I; Hekimoglu B
J Exp Clin Cancer Res; 2001 Dec; 20(4):473-80. PubMed ID: 11876539
[TBL] [Abstract][Full Text] [Related]
25. Characteristics of prostate cancer detected by digital rectal examination only.
Okotie OT; Roehl KA; Han M; Loeb S; Gashti SN; Catalona WJ
Urology; 2007 Dec; 70(6):1117-20. PubMed ID: 18158030
[TBL] [Abstract][Full Text] [Related]
26. Longitudinal PSA changes in men with and without prostate cancer: assessment of prostate cancer risk.
Berger AP; Deibl M; Steiner H; Bektic J; Pelzer A; Spranger R; Klocker H; Bartsch G; Horninger W
Prostate; 2005 Aug; 64(3):240-5. PubMed ID: 15712213
[TBL] [Abstract][Full Text] [Related]
27. Prostate Cancer Screening in the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial: findings from the initial screening round of a randomized trial.
Andriole GL; Levin DL; Crawford ED; Gelmann EP; Pinsky PF; Chia D; Kramer BS; Reding D; Church TR; Grubb RL; Izmirlian G; Ragard LR; Clapp JD; Prorok PC; Gohagan JK;
J Natl Cancer Inst; 2005 Mar; 97(6):433-8. PubMed ID: 15770007
[TBL] [Abstract][Full Text] [Related]
28. Diagnosis of advanced or noncurable prostate cancer can be practically eliminated by prostate-specific antigen.
Labrie F; Candas B; Cusan L; Gomez JL; Diamond P; Suburu R; Lemay M
Urology; 1996 Feb; 47(2):212-7. PubMed ID: 8607237
[TBL] [Abstract][Full Text] [Related]
29. Prostate-specific antigen levels in the United States: implications of various definitions for abnormal.
Welch HG; Schwartz LM; Woloshin S
J Natl Cancer Inst; 2005 Aug; 97(15):1132-7. PubMed ID: 16077071
[TBL] [Abstract][Full Text] [Related]
30. Digital rectal examination as a prostate cancer-screening method in a country with a low incidence of prostate cancer.
Shim HB; Lee SE; Park HK; Ku JH
Prostate Cancer Prostatic Dis; 2007; 10(3):250-5. PubMed ID: 17297501
[TBL] [Abstract][Full Text] [Related]
31. Prostate carcinoma among men with human immunodeficiency virus infection.
Crum NF; Spencer CR; Amling CL
Cancer; 2004 Jul; 101(2):294-9. PubMed ID: 15241826
[TBL] [Abstract][Full Text] [Related]
32. Effect of digital rectal examination on serum prostate-specific antigen in a primary care setting. The Internal Medicine Clinic Research Consortium.
Arch Intern Med; 1995 Feb; 155(4):389-92. PubMed ID: 7531426
[TBL] [Abstract][Full Text] [Related]
33. Ten year trend in prostate cancer screening with high prostate-specific antigen exposure rate in Japan.
Okihara K; Kitamura K; Okada K; Mikami K; Ukimura O; Miki T
Int J Urol; 2008 Feb; 15(2):156-60; discussion 161. PubMed ID: 18269453
[TBL] [Abstract][Full Text] [Related]
34. Prevalence of prostate cancer among men with a prostate-specific antigen level < or =4.0 ng per milliliter.
Thompson IM; Pauler DK; Goodman PJ; Tangen CM; Lucia MS; Parnes HL; Minasian LM; Ford LG; Lippman SM; Crawford ED; Crowley JJ; Coltman CA
N Engl J Med; 2004 May; 350(22):2239-46. PubMed ID: 15163773
[TBL] [Abstract][Full Text] [Related]
35. Biopsy of men with PSA level of 2.6 to 4.0 ng/mL associated with favorable pathologic features and PSA progression rate: a preliminary analysis.
Zhu H; Roehl KA; Antenor JA; Catalona WJ
Urology; 2005 Sep; 66(3):547-51. PubMed ID: 16140075
[TBL] [Abstract][Full Text] [Related]
36. Predictors of subsequent prostate cancer in men with a prostate specific antigen of 2.6 to 4.0 ng/ml and an initially negative biopsy.
Eggener SE; Roehl KA; Catalona WJ
J Urol; 2005 Aug; 174(2):500-4. PubMed ID: 16006880
[TBL] [Abstract][Full Text] [Related]
37. [Value of determining prostate-specific antigen for early detection or prostatic carcinoma].
Hammerer P; Huland H
Urologe A; 1995 Jul; 34(4):283-9. PubMed ID: 7545842
[TBL] [Abstract][Full Text] [Related]
38. Undetectable prostate specific antigen at 6-12 months: a new marker for early success in hormonally treated patients after prostate brachytherapy.
Miller N; Smolkin ME; Bissonette E; Theodorescu D
Cancer; 2005 Jun; 103(12):2499-506. PubMed ID: 15852361
[TBL] [Abstract][Full Text] [Related]
39. [Detection of cancer of the prostate. A study of 600 cases].
Teillac P; Bron J; Tobolski F; Cussenot O; Lesourd A; Leroy M; Toubert ME; Brocheriou C; Laval-Jeantet M; Le Duc A
Ann Urol (Paris); 1990; 24(1):37-41. PubMed ID: 1690963
[TBL] [Abstract][Full Text] [Related]
40. Histological diagnosis of prostate cancer in Korean men aged 70-79 years.
Shim HB; Lee SE; Park HK; Ku JH
Jpn J Clin Oncol; 2007 Oct; 37(10):782-7. PubMed ID: 17913831
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]